LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) — RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
Entdecke mehr von LabNews
Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.
